Recent guidelines on weight-loss drugs are a ‘groundbreaking’ shift in obesity treatment – The Irish Times
The treatment of weight loss has undergone a significant shift with the advent of drugs like semaglutide, known as Ozempic and Wegovy, which impact blood sugar and promote weight reduction. This change is further defined by new guidance from the World Health Organisation (WHO) and ongoing research comparing these medications to bariatric surgery.
A New Understanding of Obesity
The Scope of the Problem
Being overweight or obese elevates the risk of serious health issues, including heart disease, stroke, various cancers, type 2 diabetes, osteoarthritis, sleep apnoea, and depression. Successfully addressing rising obesity rates globally could dramatically alter the landscape of public health.
WHO’s Groundbreaking Shift
The WHO’s recent guidance represents a “groundbreaking” change in how the agency views obesity treatment, according to Dr. Francesca Celletti, who led the guideline’s development. Historically, the focus was primarily on lifestyle changes – diet and exercise – for a condition affecting over one billion people worldwide. Now, the WHO acknowledges and supports the use of GLP-1 drugs.
Cautious Optimism
The WHO guideline emphasizes combining GLP-1 prescriptions with behavioral interventions to support patient weight loss. It also acknowledges gaps in current knowledge, stating that the long-term use and safety of these medications remain unknown. Potential adverse events, such as nausea, vomiting, diarrhoea, and even acute pancreatitis, require careful consideration.
Dr. Celletti cautioned that even rare side effects could become significant if hundreds of millions of people use the drugs over the next decade, emphasizing the need for further study. Despite these cautions, experts are encouraged by emerging evidence of the drugs’ potential impact on obesity-related complications, with the hope of reversing a range of metabolic diseases.
GLP-1s and Bariatric Surgery: A Comparison
The Role of Surgery
Research suggests bariatric surgery continues to play a role, particularly in achieving substantial and lasting weight loss. One study indicated surgery resulted in approximately five times more weight loss than weekly injections of semaglutide or tirzepatide after two years. Patients undergoing bariatric surgery can lose, on average, 30 to 35 percent of their total body weight in the first year, compared to 15 to 20 percent with GLP-1 medications.
Appropriate Candidates
There is growing agreement that bariatric surgery is most suitable for individuals with severe obesity who haven’t responded adequately to lifestyle changes and weight-loss drugs. The benefits of surgery can be rapid, with up to 60 percent of patients with diabetes achieving remission.
Looking Ahead
The WHO guideline’s most significant contribution may be its classification of obesity as a complex, chronic, relapsing disease requiring ongoing, lifelong care. This positions obesity alongside conditions like hypertension and diabetes, which require continued treatment to manage effectively.
Frequently Asked Questions
What is the primary shift in the WHO’s approach to obesity?
The WHO now endorses the use of GLP-1 drugs alongside lifestyle interventions, a departure from its previous focus solely on diet and exercise.
What are some potential risks associated with GLP-1 drugs?
Known adverse events include nausea, vomiting, and diarrhoea, with potential risks of more serious side effects like acute pancreatitis. Long-term safety data is currently inconclusive.
When might bariatric surgery be considered the more appropriate option?
Surgery is generally considered most appropriate for individuals with severe obesity who have not seen sufficient results from lifestyle changes and weight-loss drugs.
As these new treatments and understandings of obesity evolve, how might healthcare systems adapt to provide comprehensive, long-term care for individuals affected by this chronic condition?